The present study was designed to prospectively test the hypothesis that gene polymorphisms of the renin-angiotensin system are associated with recurrent restenosis after repeated percutaneous transluminal coronary angioplasty. Five hundred and eleven patients after first successful angioplasty were characterized with respect to the angiotensinogen M235T, angiotensin-converting enzyme insertion/deletion and angiotensin II type 1 receptor A1166C gene polymorphisms. In 164 of these patients repeated angioplasty on a restenotic lesion was performed. After repeated angioplasty, 46 patients had recurrent restenosis as defined by a greater than 50 % progression of residual stenosis. In the recurrent restenosis group there was a statistically significant higher percentage of patients receiving cholesterol-lowering drugs compared with the group of patients without recurrent restenosis. The two groups of patients did not differ with respect to procedural and angiographic parameters. There were significantly more carriers of the angiotensinogen 235T allele in the recurrent restenosis group than in the control group without recurrent restenosis. No differences between the two groups were found with respect to the other gene polymorphisms investigated. According to the results of a multifactorial analysis of variance, only the 235T allele of the angiotensinogen gene and not cholesterol drug therapy independently affected the increase of stenosis at follow-up angiography. In conclusion, the angiotensinogen 235T allele may be an independent predictor for recurrent restenosis after repeated angioplasty.
INTRODUCTION
Repeated percutaneous transluminal coronary angioplasty (Re-PTCA) is a well-established method for the treatment of patients with restenosis after first dilation. Compared with the first angioplasty, Re-PTCA is characterized by a higher initial success rate, a lower rate of lesions according to the American Heart Association\ American College of Cardiology (AHA\ACC) classification [7] , the degree of stenosis before PTCA, the degree of residual stenosis after PTCA and the presence of the angiotensinogen (AGT) 235T allele are all independent risk factors for restenosis after a first PTCA.
The present study was designed to prospectively test the hypothesis that the AGT M235T, the angiotensinconverting enzyme insertion\deletion (ACE I\D) and the angiotensin II type 1 receptor (AT1R) A1166C gene polymorphisms are associated with recurrent restenosis after Re-PTCA.
METHODS

Study population
The study population comprised 511 consecutive patients with single or multi-vessel coronary artery disease, who participated in a routine follow-up program of cardiac catheterization 4-6 months after they had undergone a successful first PTCA without stenting on a single native vessel (by consecutive we mean that all the patients who entered the hospital ' consecutively ' during the given time period and met the inclusion criteria were included in the study). The population is identical to that described in a previous study [6] . Prior to inclusion in the study, all subjects had given informed written consent, according to the protocol approved by the local Ethical Committee. All patients were residents of Western Pomerania, a small area located in the northeast of Germany. Clinical and laboratory data were obtained from medical records. Genotyping of the 511 patients with first PTCA was performed before followup angiography. In 164 patients Re-PTCA of a restenotic lesion was performed. Re-PTCA was successful in 154 patients (93.9 %). Complete clinical and angiographic data were available from 145 patients with successful Re-PTCA. These patients formed the final cohort of the present study. In 24 of the 145 patients (16.6 %) coronary stenting (CS) was performed during Re-PTCA.
PTCA and angiographic analyses
PTCA and CS procedures were carried out by experienced therapists according to standard techniques. Pharmacotherapy included pretreatment with antiplatelet drugs (100 mg\day aspirin). In the case of CS ticlopidine (500 mg\day) was given additionally for 28 days. Angiographies were performed during PTCA and CS respectively, and at a follow-up visit 4-6 months later. Angiograms were independently assessed by visual inspection by two experienced cardiologists. Disagreements were resolved by an additional joint reading. Dilated vessels were classified according to the AHA\ ACC criteria [7] . Re-PTCA procedures were considered successful when the residual luminal narrowing in the dilated restenotic segment, immediately after repeated angioplasty, was less than 50 %. Recurrent restenosis was defined as a greater than 50 % progression of residual stenosis at the follow-up angiography compared with the findings immediately following Re-PTCA. The left ventricular ejection fraction was evaluated from left ventriculograms in the 30m right anterior oblique projection by a quantitative computer-assisted method [8] . A prior myocardial infarction was assumed in those patients who reported a positive history of myocardial infarction and whose ventriculograms showed local irregular motion of the left ventricular wall. Coronary arteries which had been subjected to angioplasty and which led to an area of irregular left ventricular wall motion were assumed to have previously caused a myocardial infarction.
Genetic analyses
Genetic analyses were performed before follow-up angiography by laboratory personnel who were blinded from the clinical data. Genomic DNA was extracted from peripheral blood leucocytes using a commercially available kit (High Pure PCR Template Preparation Kit, Boehringer Mannheim, Mannheim, Germany). Genotyping of the AGT M235T gene polymorphism was performed using a PCR\restriction fragment length polymorphism (RFLP)-based technique [9] . The sequences of the downstream and upstream primers were 5h-GAT GCG CAC AAG GTC CTG-3h and 5h-CAG GGT GCT GTC CAC ACT GGC TCG C-3h respectively. PCR products were subjected to BstUI digestions at conditions as recommended by the manufacturer (New England Biolabs, Schwalbach, Germany). The digestion products were separated on 4 % (w\v) agarose gels and visualized by ethidium bromide staining. The ACE I\D gene polymorphism was determined by PCR [10] with the modification that DMSO was added to the PCR mixture at a final concentration of 5 % (v\v). The inclusion of 5 % DMSO in the reaction mixture has been shown to improve the amplification of the I allele in ID heterozygotes [11] . To further safeguard against DD versus ID mistyping, the DNA from all patients initially typed DD was subjected to a second PCR analysis with a sense primer hybridizing at the 5h end of the insertion sequence, along with the standard antisense primer [12] . PCR products were subjected to electrophoresis in 2 % agarose gels and visualized by ethidium bromide staining. The AT1R A1166C gene polymorphism was also determined by a PCR\RFLP-based technique [13] . The sequences of the downstream and upstream primers were 5h-ATA ATG TAA GCT CAT CCA CC-3h and 5h-GAG ATT GCA TTT CTG TCA GT-3h respectively. A ' hot start ' modification of the PCR protocol was used to increase the specificity of the amplification. PCR products were digested with 5 units of DdeI (New England Biolabs, Schwalbach, Germany) at 37 mC for 2 h. The digestion products were separated on 4 % agarose gels and visualized by ethidium bromide staining.
Statistics
Data on quantitative clinical characteristics are expressed as meanspS.D. Data on qualitative characteristics are expressed as percentage values or absolute numbers as indicated. Patients were divided into two groups according to the presence or absence of recurrent restenosis. Comparisons between groups were made by χ#-test (nominal data) or Mann-Whitney test (interval data). Variables that showed significant differences between patients with and without recurrent restenosis in the initial group comparisons were further analysed by the multifactorial ANOVA. The outcome variable for the ANOVA was percentage increase of stenosis after Re-PTCA, with the vessel lumen immediately after PTCA being 100 %. A value of P 0.05 was considered statistically significant. All statistical analyses were performed with SPSS software (SPSS GmbH Software, Munich, Germany).
RESULTS
Clinical, procedural and angiographic characteristics of the patients
Forty-six (31.7 %) out of 145 patients that had undergone a Re-PTCA on the same vessel showed recurrent restenosis at follow-up angiography (Table 1) . Patients with and without recurrent restenosis did not differ from each other with respect to age, sex, body mass index and Table 1 , with the exception that there was a statistically significant higher percentage of patients receiving cholesterol-lowering drugs in the recurrent restenosis group. The two groups of patients did not differ significantly from each other with respect to the severity of lesions according to the AHA\ACC classification, the extent of stenosis before Re-PTCA, the extent of residual stenosis after Re-PTCA and several other procedural and angiographic parameters, as listed in Table 2 .
Distribution of renin-angiotensin system genotypes and recurrent restenosis
The distributions of AGT M235T, ACE I\D and AT1R A1166C genotypes in patients with and without recurrent restenosis are shown in Table 3 . In both groups the distributions of all genotypes tested were compatible with the Hardy-Weinberg equilibrium. Patients with and without recurrent restenosis differed significantly from each other with respect to the distribution of the AGT M235T, but not the ACE I\D and the AT1R A1166C genotypes. The odds ratio to develop recurrent restenosis in carriers of the AGT 235T allele was 2.56 (95 % confidence interval : 1.11-5.89).
Identification of independent risk factors
Multifactorial ANOVA comprising the two variables that showed significant differences between patients with and without recurrent restenosis in initial group comparisons (see Table 1 and 3) revealed that only the presence of the AGT 235T allele ( P 0.05) and not cholesterol-lowering drug therapy ( P l 0.18) independently affected the increase of stenosis at follow-up angiography. Significantly more patients with the 235T allele of the AGT gene (82.5 %) than patients with the 235MM genotype (57.4 %) received lipid-lowering drugs ( P 0.005, χ#-test).
DISCUSSION
Various attempts have been made to identify predictors of recurrent restenosis on the basis of patient-related, angiographic or procedural factors. Thus, male gender [4] , diabetes mellitus, hypertension [5] , severe lesions [14] , the time interval between first and Re-PTCA [4, 15] and procedural factors [3] have been reported to be associated with an increased risk for recurrent restenosis after Re-PTCA.
While we have shown previously that the 235T allele of the AGT gene is an independent risk factor for restenosis after first PTCA [6] , the present study provides evidence for an association of the same allele of the AGT gene with recurrent restenosis after Re-PTCA. To the best of our knowledge this is the first report about an association of a genetic factor with restenosis after Re-PTCA. Our finding that the 235T allele of the AGT gene is associated with an increased risk for recurrent restenosis, in a subset of patients in which we had previously found a similar association between the same allele and simple restenosis [6] , corroborates the conclusion that the M235T alleles of the AGT gene affect the local response to mechanical coronary dilatation. Obviously, we cannot rule out that mechanisms related to the renin-angiotensin system are particularly important for the response to PTCA in our cohort as opposed to other populations. However, this restriction applies to any genetic association study which therefore generally requires independent confirmation.
The mechanisms by which the AGT M235T alleles affect the risk for recurrent restenosis after Re-PTCA remain unknown. It has been shown that the AGT 235T allele is associated with increased plasma AGT levels [16] . Furthermore, recent studies [17] [18] [19] [20] have demonstrated that the M235T alleles of the AGT gene are in linkage disequilibrium with allelic variants in the AGT promoter region (A-6G and A-20C), which may affect the basal rate of AGT transcription and could account for phenotypic variation in plasma AGT concentrations. Experimental evidence suggests that the renin-angiotensin system may be involved in the vascular response to injury. Thus, the local expression of the components of the renin-angiotensin system is enhanced after balloon injury of rat carotid arteries [21] [22] [23] [24] . Angiotensin II, the effector peptide of the renin-angiotensin system, is known to stimulate vascular smooth muscle cell growth [25] and matrix synthesis [26] and to inhibit fibrinolysis [27, 28] .
In addition to the AGT 235T allele, there was only one other factor, the frequency of cholesterol-lowering drug therapy, that was statistically associated with recurrent restenosis after Re-PTCA. This is in agreement with a study [29] in two Japanese populations that found a weak, albeit not statistically significant, association between the AGT M235T genotype and serum levels of total cholesterol. While this finding suggests that hyperlipidemia may have been more prevalent in patients with recurrent restenosis, the frequency of cholesterol-lowering drug therapy was not an independent risk factor, as indicated by the results of multifactorial ANOVA in our study. Furthermore, although some reports have suggested that hyperlipidemia may be associated with an increased rate of restenosis after coronary angioplasty [30] [31] [32] , other studies [33, 34] did not confirm these results.
In our previous study [6] severe stenosis before PTCA and little residual stenosis immediately after PTCA were associated with an increased risk for simple restenosis. In the present study none of the angiographic parameters investigated was associated with the risk for recurrent restenosis. It is conceivable that restenosis after first PTCA and recurrent restenosis after Re-PTCA are mediated in part by different pathophysiological mechanisms. Thus, there is evidence that angiographic variables such as residual stenosis may be decisive for the development of restenosis after first PTCA, but may be less important for the development of restenosis after Re-PTCA [3, 35] . The results of the present study would support this concept.
In summary, our data provide evidence for an association of the angiotensinogen 235T allele with recurrent restenosis after a Re-PTCA.
